Background: N-acetylcysteine, sodium bicarbonate, statins, and ascorbic acid have been studied for reducing contrastinduced nephropathy (CIN).
I
odine contrast medium is an essential component of many diagnostic and therapeutic procedures that involve medical imaging. One important side effect of iodine contrast is contrast-induced nephropathy (CIN), defined as an increase in serum creatinine levels of more than 25% or 44.2 μmol/L (0.5 mg/dL) within 3 days of intravascular administration in the absence of an alternative cause (1) . Because of increasing use of contrast media in radiologic and cardiologic procedures and the increasing prevalence of persons who are vulnerable to CIN (those with chronic kidney disease, diabetes mellitus, or hypertension, as well as elderly persons), kidney failure due to CIN is a substantial concern (2, 3). The reported incidence varies between 7% and 11% depending on the definition of CIN, study population, and setting (2) (3) (4) . Some studies suggest that this incidence may be overestimated (4) , especially when intravenous (IV) contrast media are used. An average additional cost of $10 345 is associated with a CIN-related hospital stay (5) .
Many strategies have been used to prevent CIN. They include oral hydration; volume expansion with sodium chloride or bicarbonate or both; administration of N-acetylcysteine; withdrawal of metformin, angiotensinconverting enzyme inhibitors, angiotensin II-receptor blockers, or nonsteroidal anti-inflammatory drugs; hemofiltration or hemodialysis; statins; use of low-osmolar contrast media (LOCM), iso-osmolar contrast media (IOCM), or nonionic contrast media; and reducing the volume of contrast media administered. Despite these varied strategies, no clear consensus exists in clinical practice about the most effective intervention to prevent or reduce CIN.
Many meta-analyses have been published, but almost all of them have focused on specific therapies or included subspecialty-specific populations, which reduced the general applicability in clinical practice (6 -11) . The route of administration of contrast media may be a confounder because the baseline risk profile of patients having intra-arterial (IA) versus IV procedures may differ. Whether effectiveness of preventive interventions depends on the route of administration or the type of contrast media (IOCM or LOCM, the 2 types now in regular clinical use in the United States) is also unclear. We did a systematic review and meta-analysis to compare the preventive effect of strategies to reduce CIN, including subgroup analyses based on route of administration of contrast media or preventive strategies and the type of contrast media used.
Data Extraction and Quality Assessment
Two reviewers independently screened the titles and abstracts for eligibility and independently assessed each study's risk of bias by using 5 items from the Cochrane Risk of Bias Tool for RCTs (3). We solved disagreements by consensus or a third reviewer when consensus was not possible. At random intervals during screening, we did quality checks to ensure that eligibility criteria were applied consistently. The second reviewer checked the accuracy of the data extracted by the first reviewer.
We graded the strength of evidence (SOE) on comparisons of interest for the key outcomes by using the grading scheme recommended in the Methods Guide of the Evidence-based Practice Center and considered the domains of study limitations, directness, consistency, precision, reporting bias, and magnitude of effect (13) . Following the guidance of the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) Working Group (14), we rated evidence as precise if the total number of patients exceeded an optimum information size and the 95% CI excluded a risk ratio (RR) of 1.0. If the number of patients exceeded the optimum information size and the CI did not exclude the possibility of no difference (that is, RR of 1.0), we only rated the evidence as precise if the CI excluded the possibility of a clinically important benefit or harm (that is, RR <0.75 or >1.25). We classified the SOE pertaining to each comparison into 4 category grades (high, moderate, low, and insufficient) and assigned SOE grades by group consensus. The body of evidence was considered high-grade if study limitations were low and there were no problems in any other domain, and it was subsequently downgraded for each domain in which a problem was identified. If the magnitude of effect was very large, the SOE could be upgraded.
Data Synthesis and Analysis
The primary outcome was CIN, defined as an increase in serum creatinine levels of more than 25% or 44.2 μmol/L (0.5 mg/dL) within 3 days of intravascular administration of contrast media. We calculated individual study RRs and CIs and then obtained overall and subgroup summary RRs by using a random-effects model. For large comparisons with 18 or more studies, we used the DerSimonian-Laird random-effects estimator, with the estimate of heterogeneity taken from the inverse-variance, fixed-effect model (15) . Although this method is often the standard estimator used by many meta-analysis software programs, it tends to underestimate CIs when fewer than 18 studies are compared (15) . To compensate, we used the Knapp-Hartung small-sample estimator approach for comparisons with fewer than 18 studies. This method allows for small sample adjustments to the variance estimates and calculates CIs on the basis of the t distribution with k Ϫ 1 degrees of freedom (15) . We used the Harbord modified test for small study effects to determine whether there was asymmetry in effect estimates.
To assess the clinical importance of differences in CIN incidence, a binary outcome, we followed guidance for selecting a minimally important difference on the basis of the overall event rate in the studies (14) . Our clinical experts decided that a relative risk reduction of 25% would be clinically important, which is consistent with the guidance that suggests a reduction of 20% to 30% in determining optimal information size.
To account for factors that could be associated with a difference in CIN risk, we did a subgroup analysis on the basis of the route of administration (IA vs. IV) and type of contrast media (IOCM vs. LOCM), baseline serum creatinine level, sex, age, and prevalence of diabetes mellitus. A priori, we assumed that there would be considerable heterogeneity and therefore used a random-effects model. We also examined the I 2 , which measures the degree of heterogeneity across studies (I 2 varies from 0% to 100%, with 0% indicating no het-erogeneity). All statistical analyses were done in Stata, version 13 (StataCorp).
Role of the Funding Source
The Agency for Healthcare Research and Quality selected the topic and assigned it to the Johns Hopkins University Evidence-based Practice Center. The Agency assigned a task order officer who provided comments on the protocol and draft versions of the full evidence report. The Agency did not directly participate in the literature search, determination of study eligibility, data analysis or interpretation, or preparation of the manuscript for publication.
RESULTS
The literature search revealed 86 RCTs on interventions for preventing CIN (Appendix Figure, available at www.annals.org). These study results were published between 1998 and 2015. Six studies were funded by industry sources (16 -21) , 16 were funded by academia or government agencies, 33 had no funding statement, and the remainder reported no conflicts of interest. All findings from these studies were analyzed and described in the full report (12) .
N-acetylcysteine Plus IV Saline Versus IV Saline
N-acetylcysteine is a direct scavenger of free radicals and improves blood flow through nitric oxidemediated pathways, which results in vasodilatation. As a result, both the antioxidant and vasodilatory properties of N-acetylcysteine are believed to protect against CIN.
We included 54 RCTs on N-acetylcysteine plus IV saline versus IV saline with or without a placebo published since 2002 in the meta-analysis (16 -69) .
The studies varied widely in patient and intervention characteristics. Study patients had renal dysfunction at baseline (defined as serum creatinine levels >106.08 μmol/L [>1.2 mg/dL]) in 35 studies. Table 1 summarizes the pooled RRs and CIs for subgroups by high-or low-dose N-acetylcysteine administration, route of administration (oral or IV), and type of contrast media (LOCM or ICOM). Pooled RRs for CIN and CIs were derived by using a random-effects model to pool studies comparing N-acetylcysteine with IV saline versus IV saline with or without a placebo.
High-dose N-acetylcysteine plus IV saline had a small effect on reducing CIN risk that was clinically unimportant and not statistically significant, and low-dose N-acetylcysteine plus IV saline had a borderline clinically important effect on preventing CIN. Both comparisons had low SOE. Sensitivity analyses revealed imprecise estimates of the pooled RR for CIN, when stratified by route of administration ( Table 1) . When given orally, N-acetylcysteine plus IV saline had a small effect on reducing CIN risk that was clinically unimportant but statistically significant, with low SOE. N-acetylcysteine plus IV saline had a clinically important benefit in reducing CIN risk when LOCM were used, with moderate SOE, but had a clinically unimportant effect when IOCM were used, with low SOE (Figure 1 ). We examined how the RRs varied according to baseline characteristics of the study population and did not see any significant difference by age, sex, baseline renal function, or the presence or absence of diabetes mellitus. We did not see a pattern indicative of a trend by study quality.
The overall analysis did not suggest that any intervention was superior when we evaluated secondary outcomes, and the SOE was low or insufficient. The Harbord test for small study effects was done for all comparisons, and no asymmetry was detected ( Table 2) .
IV Sodium Bicarbonate Versus IV Saline
A major hypothesis for using IV sodium bicarbonate to prevent CIN is that the alkalinization of tubular fluid diminishes the production of free oxygen radicals, which may cause CIN.
We included 19 RCTs on IV sodium bicarbonate versus IV saline (21, 35, 48, 59, 62, 69 -82) . The studies varied widely in patient and intervention characteristics. Study patients had renal dysfunction at baseline in 10 studies. Contrast medium was administered via IV in 2 studies, IA in 14 studies, and IA or IV in 1 study, and 1 study did not report the route of administration. Six studies used IOCM, 12 used LOCM, and 1 did not report the type of contrast media (Supplement, available at www.annals.org).
Intravenous sodium bicarbonate did not have a clinically important effect on CIN risk when compared with IV saline in all studies (pooled RR, 0.93 [95% CI, 0.68 to 1.27]). Intravenous sodium bicarbonate led to a clinically important reduction in CIN that was not statistically significant when compared with IV saline in patients receiving LOCM (RR, 0.65 [CI, 0.33 to 1.25]) and did not lead to reduction in CIN in patients receiving IOCM (RR, 1.02 [CI, 0.70 to 1.48]) ( Figure 2) . The SOE was low for all comparisons of IV sodium bicarbonate ( Table 2) .
The overall analysis did not suggest that IV sodium bicarbonate was superior to IV saline when we evaluated secondary outcomes, and the SOE was low or insufficient. The Harbord test for small study effects was done for all comparisons, and no asymmetry was detected ( Table 2) . CIN = contrast-induced nephropathy; IA = intra-arterial; IOCM = isoosmolar contrast media; IV = intravenous; LOCM = low-osmolar contrast media; NAC = N-acetylcysteine; RR = risk ratio.
N-acetylcysteine Plus IV Saline Versus Sodium Bicarbonate
We included 7 RCTs (n = 1619) (21, 35, 48, 59, 62, 69, 83) that compared N-acetylcysteine with sodium bicarbonate (6 studies used IA administration, 1 did not report route of administration; 4 used LOCM, 3 used IOCM) (Supplement). This comparison showed no clinically important benefit in reducing CIN risk in 1 intervention over the other (RR, 1.11 [CI, 0.51 to 2.41]). The CI was so wide that we could not rule out the possibility of an important decrease or important increase in CIN risk ( Figure 2) . The SOE was graded as insufficient to draw conclusions about potential differences between the interventions in any outcome evaluated. The Harbord test for small study effects was done, and no asymmetry was detected ( Table 2) .
Statins
Statins have cholesterol-independent functionalities that play a role in various clinical contexts. The proposed mechanism related to CIN prevention is that they acted as stabilizers of the endothelium and freeradical scavengers in a model of ischemic nephropathy (84) .
We did 2 separate meta-analyses on the studies of statins to reduce CIN incidence in patients receiving IA contrast. One analysis included 8 studies (n = 5024) on statin-naive patients that compared a statin plus IV saline with IV saline alone (85) (86) (87) (88) (89) (90) (91) (92) . Two of the studies included only patients with chronic kidney disease, 3 included only those with cardiac issues, and 2 included patients with diabetes mellitus and chronic kidney disease. The analysis showed that statins had a clinically important but not statistically significant effect on reducing CIN risk (RR, 0.68 [CI, 0.39 to 1.20]) and low SOE ( Table 2 and Figure 2 ). When we evaluated secondary outcomes, the SOE was insufficient to determine whether any intervention was superior.
Five studies (n = 1477) compared statins added to N-acetylcysteine and IV saline with N-acetylcysteine plus IV saline (93) (94) (95) (96) or sodium bicarbonate (97) (Supplement). Two of these studies included only patients with chronic kidney disease, 1 included those with cardiac disorders, 1 had a general population, and 1 had patients with diabetes mellitus and chronic kidney disease. Seven studies were not included in the metaanalyses because they included comparisons that were not similar enough to analyze (98 -104) or did not include a CIN outcome (105) . The analysis showed a clinically important and statistically significant reduction in CIN (RR, 0.52 [CI, 0.29 to 0.93]) ( Figure 2) and low SOE. When we evaluated secondary outcomes, the SOE was graded as insufficient. The Harbord test for small study effects was done for all comparisons, and no asymmetry was detected ( Table 2) .
Ascorbic Acid
As an antioxidant, ascorbic acid acts as a scavenger of reactive oxygen species, reducing oxidative stress and possibly preventing CIN.
We identified 8 RCTs (n = 2026) that compared ascorbic acid with IV saline or N-acetylcysteine and included 6 in the meta-analysis (32, 106 -110). We did not include 2 of the studies because they included N-acetylcysteine in both groups (111, 112) . These studies included patients receiving cardiovascular interventions with IA administration of LOCM (3 Only 1 study Imprecise Insufficient SOE to determine effect CIN = contrast-induced nephropathy; IOCM = iso-osmolar contrast media; IV = intravenous; LOCM = low-osmolar contrast media; NAC = N-acetylcysteine; RRT = renal replacement therapy; SOE = strength of evidence. * All studies were randomized, controlled trials and were direct. (Figure 2) . The SOE was low for both comparisons and insufficient for all secondary outcomes. The Harbord test for small study effects was done for all comparisons, and no asymmetry was detected ( Table 2) .
DISCUSSION
Many interventions to reduce CIN risk have been studied, but to date, the evidence has been inconclusive. In our analysis, evidence of a clinically important and statistically significant benefit was seen in studies of the following 3 comparisons: low-dose N-acetylcysteine plus IV saline versus IV saline (low SOE), N-acetylcysteine plus IV saline versus IV saline in patients receiving LOCM (moderate SOE), and statins plus N-acetylcysteine versus N-acetylcysteine (low SOE). A clinically important but statistically insignificant benefit was seen in studies of the following 3 comparisons: sodium bicarbonate versus IV saline in patients receiving LOCM (low SOE), statins plus IV saline versus IV saline alone (low SOE), and ascorbic acid plus IV saline versus IV saline (low SOE).
Our results are similar to the most recent metaanalysis on the effect of statins, published with a search end date of March 2014 (6), although that metaanalysis did not do a sensitivity analysis on the basis of IV saline or N-acetylcysteine administration along with statins. Despite previous reviews highlighting evidence on the effectiveness of statins to prevent CIN, they are not routinely used in clinical practice and we are not aware of any guidelines that recommend them for this indication. The findings reported in these studies could be partly explained by their direct effect on glomerular filtration rates that is independent of a protective effect on kidney function, as has been reported in 1 study (113) . With increasing recognition of the cholesterolindependent vascular effects of statins, we need to reassess the role of statins in preventing CIN, especially because they are readily available, easy to administer, and relatively inexpensive.
Compared with IV saline alone, low-dose N-acetylcysteine plus IV saline had a clinically important decrease in CIN in patients receiving either IA or IV contrast media or when either low or high doses were used in patients receiving LOCM. The SOE was low for the first comparison (low-dose N-acetylcysteine) and moderate for the second comparison (in patients receiving LOCM), primarily because of limitations in the quality of studies and inconsistency in results. Our results are consistent with a recent meta-analysis that ended its search in September 2013 (7) and did not include sensitivity analysis by type of contrast media or high versus low doses. The low SOE may explain why low-dose N-acetylcysteine is not used more often and helps to explain differing recommendations on its use to prevent CIN. The joint American College of Cardiol- ogy/American Heart Association 2012 guideline recommends against the use of N-acetylcysteine for patients receiving IA contrast media in cardiac procedures (114) , whereas the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Acute Kidney Injury suggests using oral N-acetylcysteine with IV fluids in patients with increased CIN risk, acknowledging low SOE (115). Although N-acetylcysteine is inexpensive and seems to be safe, the evidence may not be strong enough to support routine use, especially without more robust evidence of clinical outcomes other than CIN incidence. Our analysis is less positive about the effectiveness of IV sodium bicarbonate compared with IV saline relative to recent meta-analyses by Jang (8) and Zhang (9) and their colleagues with search end dates of January 2012 and August 2014, respectively. Another metaanalysis reported that sodium bicarbonate was superior to IV saline (8) but included studies using a combination of IV sodium bicarbonate and N-acetylcysteine that we did not want to include in the comparison of sodium bicarbonate and IV saline. The meta-analysis by Zhang and colleagues (9) reported that sodium bicarbonate plus N-acetylcysteine was better than sodium bicarbonate alone, but that conclusion was based on a single study that used the combination of sodium bicarbonate plus N-acetylcysteine. All 3 meta-analyses suggested that sodium bicarbonate could benefit patients receiving LOCM, but we did not find a statistically significant benefit.
Although our meta-analysis suggested a possible clinical benefit for ascorbic acid plus IV saline compared with IV saline alone, the difference was not statistically significant. The SOE was low because the studies had important limitations, the comparators varied too much, and the effects were inconsistent and imprecise.
Future studies of the comparative effectiveness of interventions for preventing CIN should stratify patients according to baseline risk for CIN, especially because detecting a treatment effect in patients with low risk may be difficult. More research could strengthen the evidence about whether N-acetylcysteine or IV sodium bicarbonate is beneficial in a particular clinical context, such as patients with increased CIN risk who receive LOCM. The clinically important benefit of statins plus N-acetylcysteine demonstrated in this analysis provides a rationale for studies investigating whether the effect differs by dose, timing of administration, type of contrast media, or baseline risk of the patient population. Future studies could be done in persons without cardiovascular risk factors to determine whether the effectiveness of statin therapy for reducing CIN occurs in the absence of physiologic effects of statins on coexisting cardiovascular disease.
Applying existing evidence to patients receiving IV contrast media is difficult because most studies involved patients receiving IA contrast media for cardiovascular procedures. More research is needed to determine the effectiveness of interventions for preventing CIN in patients receiving IV contrast media because little evidence exists on the effectiveness of different regimens for hydration when administering contrast media.
Our search was broad but our meta-analysis may overestimate the effect of prevention strategies to reduce CIN if studies with negative results were not reported in our sources. The studies span over 2 decades, and there may have been changes in the practice of CIN prevention, such as increased screening, variation in definition of acute kidney injury, and variation in hydration, over time. Such changes could contribute to differences in outcomes.
This comprehensive review highlights the generally low SOE on interventions for preventing CIN while indicating that the greatest reduction in CIN risk has been achieved with low-dose N-acetylcysteine plus IV saline in patients receiving LOCM or with statins plus N-acetylcysteine plus IV saline. 
